Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 23, 2017

View Archived Issues

NIAID begins phase I study of mosquito-borne disease vaccine candidate

FDA issues complete response letter for Amphastar's intranasal naloxone

Affigen closes series A financing to support development of cancer immunotherapies

Truxima becomes the first biosimilar MAb in oncology to be granted E.U. marketing authorization

BIIB-076 enters phase I study for Alzheimer's disease

RON kinase, a potential new therapeutic target for cancer-induced bone destruction and osteoporosis

Aeolus Pharmaceuticals starts phase I study of new formulation of AEOL-10150

FDA approves Revlimid as maintenance therapy in multiple myeloma after autologous HSCT

Phase IIa data for GSK-2330672 in patients with primary biliary cholangitis with pruritus

Prometic Life Sciences reports results from phase II study of PBI-4050 in IPF

UB-421 monotherapy shows promise for HAART substitution

ImmusanT completes phase Ib study of Nexvax2

Kalytera Therapeutics reports phase IIa results for cannabidiol in GvHD

IMDC recommends discontinuation of ADAPT trial of rocapuldencel-T

Auris Medical extends collaboration with King's College London

Revive Therapeutics and InMed in term sheet agreement for cannabinoid therapies for kidney diseases

Phytecs and Yissum Research Development establish partnership

University of South Australia patents CDK4/cyclin D1 and/or CDK6/cyclin D3 inhibitors

FDA grants priority review to Zykadia sNDA for first-line treatment of ALK-positive NSCLC

NEOMED Institute discovers new bromodomain-containing protein 4 inhibitors

Achaogen announces milestone in development of plazomicin TDM assay

Sanofi launches Mozobil in Japan

NIH leads phase I study of DS-Cav1 vaccine for RSV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...